Aaron T. Gerds - Concepedia

Author

Aaron T. Gerds

Also Known As

A Gerds, A T Gerds, A. Gerds, A. T. Gerds, A.T. Gerds, AT Gerds, Aaron T. Gerds, Aaron Gerds, Aaron T Gerds, Aaron T. Gerds

720

Publications

6.6K

Citations

H-Index

Concepts

All Affiliations

Cleveland Clinic The University of Texas MD Anderson Cancer Center Moffitt Cancer Center Memorial Sloan Kettering Cancer Center Icahn School of Medicine at Mount Sinai

About

Aaron T. Gerds is an author at Cleveland Clinic specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	36	2K
2	Health Sciences	11	12	399
3	Public Health	4	4	96
4	Engineering	2	2	90
5	Biomedical Engineering	1	1	28

Aaron T. Gerds

119

Publications

5.5K

Citations

H-Index

Page 1

	Year	Citations
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer Charles E. Geyer, Judy E. Garber, Richard D. Gelber, Annals of Oncology Breast OncologyOverall SurvivalMedicinePathologyGermline Pathogenic Variants	2022	404
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis John Mascarenhas, Ronald Hoffman, Moshe Talpaz, JAMA Oncology	2018	358
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults Michael R. Savona, Luca Malcovati, Rami S. Komrokji, Blood	2015	190
Pretransplantation Therapy with Azacitidine vs Induction Chemotherapy and Posttransplantation Outcome in Patients with MDS Aaron T. Gerds, Ted Gooley, Elihu H. Estey, Biology of Blood and Marrow Transplantation	2012	176
Development and Validation of a Novel Acute Myeloid Leukemia–Composite Model to Estimate Risks of Mortality Mohamed L. Sorror, Barry E. Storer, Amir T. Fathi, JAMA Oncology	2017	168
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study Srđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi, The Lancet Hematological MalignancyBone Marrow FailureMomelotinib Versus DanazolSymptomatic PatientsHematology	2023	164
Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer Remco J. Molenaar, Surbhi Sidana, Tomas Radivoyevitch, Journal of Clinical Oncology	2017	154
NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018 Ruben A. Mesa, Catriona Jamieson, Ravi Bhatia, Journal of the National Comprehensive Cancer Network Mixed-phenotype Acute LeukemiaNccn Guidelines InsightsMyeloproliferative NeoplasmsPathologyNccn Guideline Insights	2017	151
Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes Aziz Nazha, Mayur Narkhede, Tomas Radivoyevitch, Leukemia Hematological MalignancyTreated PatientsMedicineMixed-phenotype Acute LeukemiaPrognosis	2016	150
Reduced-Intensity Hematopoietic Cell Transplantation for Patients with Primary Myelofibrosis: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research Vikas Gupta, Adriana K. Malone, Parameswaran Hari, Biology of Blood and Marrow Transplantation	2013	143

Page 1